linjc16/ctgov huggingface dataset:
The Clinical Application of Infrared Thermal Imaging Detecting Venous Thromboembolism

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effectiveness of infrared thermal imaging in adjunctive diagnostic screening for lower limb deep venous thrombosis (DVT).

Official Title
-----------------
The Clinical Application of Infrared Thermal Imaging Detecting Venous Thromboembolism

Conditions
-----------------
Deep Venous Thrombosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing to participate in the trial and sign the informed consent form, Aged: 18-75 years. They had been definitively diagnosed with venous thromboembolism, The bed-rest immobilization time should be more than 72 hours, Planing to gynecology operation, The D dimer should be more than500 g • L-1, There is no obvious symptoms of systemic infection two weeks before the test, There is no trauma, infection, biopsy or puncture, hemorrhage and tumor in the corresponding detection site (chest and lower limbs), There is no skin disease, heart, liver, kidney, gastrointestinal tract, hematopoietic system and mental, neurological has no serious diseases. Exclusion Criteria: Patients can not be good partners, Doctors believe that there is any inappropriate situations.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Using the Infrared Thermal Imaging to detecting Venous Thromboembolism | ① Different levels of pseudocode (white, red, pink, yellow, green, blue, black) representing related IRTI that corresponds to a color scale bar of low to high temperatures, so we can know disease's position, extent and severity by comparing with the difference of color distribution and shape in the thermal imaging. ②The intensity of thermal distribution is higher than normals (great than or equal 0.5 Celsius degree is unnoraml), the symmetry of thermal range is relatively increased (pixels over 0.5   1.0-fold), the difference of spatial distribution of the thermal field and the difference of statistically analyze are related to the disease. | up to 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
infrared thermal imaging, deep venous thrombosis
Study for the Development and Validation of Chronic Cough Patient Perspective Questionnaire

Study Overview
=================
Brief Summary
-----------------
Starting from Chronic Cough Impact Querstionnaire (CCIQ), of which we are the authors and copyright holders, it will be developed and validated a shortened version with psychometric properties allowing the use in the evaluation of single patient (Chronic Cough Patient Perspective). The CCPP will allow to unmask the problem, reduce underdiagnosis, increase awareness on chronic cough, measure the impact of the chronic cough and its treatments on the patient's life.

Official Title
-----------------
Retrospective and Prospective Observational Study for the Development and Validation of Chronic Cough Patient Perspective Questionnaire

Conditions
-----------------
Chronic Cough

Intervention / Treatment
-----------------
* Other: questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of RCC (Residual Cough VAS:>10/100 mm)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: questionnaire|Assessment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) impact on HRQoL of the explored population and relationship with clinical variables. Development of a web application of the questionnaire.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Chronic Cough Impact Questionnaire (CCIQ) | To develop the preliminary CCPP questionnaire starting from Chronic Cough Impact Questionnaire (CCIQ) (2) and available database | february 2023 |
Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia

Study Overview
=================
Brief Summary
-----------------
To analyze and evaluate the efficacy and safety of octreotide subcutaneous injection in the treatment of diazazine-ineffective congenital hyperinsulinemia (CHI) in children.

Detailed Description
-----------------
Octreotide subcutaneous injection is effective and safe in the treatment of congenital hyperinsulinemia in children with inefficacy of diazazine.

Official Title
-----------------
Beijing Children's Hospital, Capital Medical University, National Center for Children's Health

Conditions
-----------------
Congenital Hyperinsulinaemic Hypoglycaemia, Octreotide Adverse Reaction

Intervention / Treatment
-----------------
* Drug: Octreotide Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consistent with the diagnosis of congenital hyperinsulinemia with ineffective diazine; With the maximum dose of diazine at 15mg/kg/d for 5 days, fasting blood glucose/postprandial blood glucose could not be stabilized at the target value of 3.3mmol/L without intravenous glucose infusion. patients treated with octreotide subcutaneous injection. Exclusion Criteria: Before the diagnosis of CHI and the treatment related to CHI, the child had received total pancreatectomy without octreotide Secondary hypoglycemia caused by diseases other than CHI Patients who refused to take octreotide due to parents or family economic reasons, but not hospital treatment factors. Patients who intervene/interfere with octreotide treatment regimen for parental reasons

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Octreotide Injection|Octreotide subcutaneous injection for congenital hyperinsulinemia with ineffective diazine|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood glucose | Maintain target blood glucose ≥3.3mmo/L | 1 year |
How to Identify Fatigue in Stroke Patients

Study Overview
=================
Brief Summary
-----------------
This study will translate an English case definition of poststroke fatigue and validate it against the Multidimensional Fatigue Questionnaire-20 and the Fatigue Severity Scale

Official Title
-----------------
How to Identify Fatigue in Stroke Patients: Validity of the Post-stroke Fatigue Case Definition

Conditions
-----------------
Post Stroke Fatigue, Stroke

Intervention / Treatment
-----------------
* Other: questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a clinical stroke within the last 6 months as judged by a senior doctor or by the research assistant. Patients that have given written informed consent - Exclusion Criteria: Patients with aphasia, dementia or cognitive deficits so severe that they are unable to understand the purpose of the interview and the questionnaire. -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: questionnaire|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean MFI-20 score for case positive patients | Describes validity of the case definition with regards to the MFI-20 questionnaire | at inclusion in the trial | 
| Mean FSS-7 score for case positive patients | Describes validity of the case definition with regards to the FSS-7 questionnaire | At inclusion in the trial | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| inter rater variability of the case definition | Reinterview by a second interviewer | within a week | 
| Optimal cut off score for case positiveness on MFI-20 and FSS | decide the optimal cut-off score on the two questionnaires to define case positiveness | at inclusion in the trial (which is the time the values used are measured) |
Clarksdale Diabetes and Metabolism Clinic CHEC Study

Study Overview
=================
Brief Summary
-----------------
This study will involve established clinic patients. The Rapid Estimate of Adult Literacy in Medicine will be administered during patients' regular clinic visits. Patients will then be referred to the Consumer Health Education Center (CHEC)by healthcare providers who will fill out a referral form. The form will be given the the CHEC health educator who will assist patients in finding literacy-appropriate health information. BMI and Hgb A1c values will be compared after 3 months and 6 months to baseline values. It is hypothesized that objective assessment of patient use of literacy-appropriate, health information from the Clarksdale Diabetes and Metabolism Clinic CHEC will improve Hgb A1c and BMI values among patients.

Official Title
-----------------
Clarksdale Diabetes and Metabolism Clinic Consumer Health Education Center Study

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Behavioral: Education


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Established patients of the Clarksdale Diabetes and Metabolism Clinic between the ages of 18 and 64. Exclusion Criteria: Individuals who are not established patients of the clinic and are not between the ages of 18 and 64.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| I<br>Established patients at the Clarksdale Diabetes and Metabolism Center | Behavioral: Education<br>* Patients will receive literacy appropriate health information.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hgb A1C and BMI measurements will improve |  | 3 and 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetic patients at the Clarksdale Diabetes, and Metabolism Clinic and must be between the, ages of 18 and 64 years of age.
Evaluating the Effectiveness of Paclitaxel-eluting Balloons for Below-the-knee Angioplasty in Patients With Critical Limb Ischemia

Study Overview
=================
Brief Summary
-----------------
to evaluate the the effectiveness of paclitaxel-eluting balloon for below-the-knee angioplasty in terms of restenosis at 12 months

Conditions
-----------------
Critical Limb Ischemia

Intervention / Treatment
-----------------
* Procedure: paclitaxel eluting balloon angioplasty in below-the-knee lesions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age>18 years angiographic stenosis>50% or occlusion of one below-knee vessel Exclusion Criteria: allergy to Paclitaxel contraindication for combined antiplatelet treatment life expectancy <1 year hypersensitivity or contraindication to one of the study drugs lack of consent need for amputation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PEB angioplasty<br>paclitaxel eluting balloon angioplasty in below-the-knee lesions | Procedure: paclitaxel eluting balloon angioplasty in below-the-knee lesions<br> <br> * Other names: FREEWAY™ (Eurocor GmbH);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| angiographic binary restenosis | incidence of binary restenosis | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
critical limb ischemia, drug-eluting balloon, restenosis
Study to Determine a Preference Between Sildenafil or Tadalafil Treatment for Problems Getting an Erection

Study Overview
=================
Brief Summary
-----------------
To determine if men with problems getting and keeping an erection prefer treatment with tadalafil or sildenafil.

Official Title
-----------------
Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Assessment of Treatment Preference

Conditions
-----------------
Impotence

Intervention / Treatment
-----------------
* Drug: tadalafil
* Drug: sildenafil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: History of erection problems Anticipate a monogamous female sexual relationship Abstain from other erection treatments throughout the study Currently use sildenafil Exclusion Criteria: Other primary sexual disorders History of radical prostatectomy or other pelvic surgery that affected being able to have an erection History of penile implant or clinically significant penile deformity. Nitrate use Certain heart problems

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>sildenafil treatment for at least 10 weeks prior to a 1 week wash out | Drug: sildenafil<br>* Current users of sildenafil citrate for a minimum of 6 weeks prior to visit 1 will continue with an individual dosage to be taken no more than once a day for an additional 4 weeks.<br>|
| Active Comparator: 2<br>Tadalafil treatment for 8 weeks following the 1 week washout period. | Drug: tadalafil<br>* 20 mg tadalafil tablets taken by mouth, as needed, no more than once a day for 8 weeks.<br>* Other names: IC351;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient choice of drug at visit 5 |  | 14-15 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PAIRS self-administered scale scores |  | 14-15 weeks |
The Accuracy of Automated Audiometry Application on Smart Phone to Screen Hearing Loss

Study Overview
=================
Brief Summary
-----------------
The purpose of study is to determine the diagnostic value of Hearing test program on smart phone for detected patients who has hearing loss.

Conditions
-----------------
Hearing Loss

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient who underwent hearing test in our otologic clinic Exclusion Criteria: Age below 15 year Patients who cannot following command

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The accuracy of automated audiometry application on smart phone to screen hearing loss |  | Two years |
Comparison of Restoration in Vitreous Hemorrhage Patients With DME After or Not Removing Inner Limiting Membrane

Study Overview
=================
Brief Summary
-----------------
This study is conducted to compare the anti-VEGF effect and visual function in vitreous hemorrhage patients with diabetic macular edema after pars plana vitrectomy with inner limiting membrane peeling or not

Official Title
-----------------
Comparative Study of Anti-VEGF Effect and Visual Function in Vitreous Hemorrhage Patients With Diabetic Macular Edema After Pars Plana Vitrectomy With Inner Limiting Membrane Peeling or Not

Conditions
-----------------
Macular Edema Due to Diabetes Mellitus, Vitreous Hemorrhage

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with vitreous hemorrhage with diabetic macular edema and require vitreous surgery Exclusion Criteria: The patient's preoperative vitreous hemorrhage resulted in the failure of OCT to scan the macular region The patient with a history of anti-VEGF therapy Patients with DME in the contralateral eye requiring anti-VEGF therapy Patients with contraindications of vitreous cavity resection The patient has a history of intraocular surgery The patient has active inflammatory disease The patient has other retinal diseases that affect vision The patient has other systemic diseases that required treatment with anti-VEGF drugs Patient with contraindications to anti-VEGF therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| control group<br>Diabetic macular edema patient with inner limit membrane | |
| experimental group<br>Diabetic macular edema patient with inner limit membrane peeling | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thickness change of retinal macular area | measurement of thickness of retinal macular area with macular optical coherence tomography after operation (0 day, 1 week, 1 months, 3 months, 6 months, 12 months) | 12 months | 
| Change of visual acuity | measurement of distance visual acuity with subjective refraction after operation (0 day, 1 week, 1 month, 3 months, 6 months, 12 months) | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of eye pressure | Measurement of contact tonometry with iCare TA01i tonometer after operation (0 day, 1 week, 1 month, 3 months, 6 months, 12 months) | 12 months | 
| B-mode ultrasound imaging | Existing or not of abnormal anatomical structure in posterior eye segment (0 day, 1 week, 1 month, 3 months, 6 months, 12 months) | 12 months |
Natto Supplementation to Prevent Loss of Bone Mass in Women Immediately After Menopause

Study Overview
=================
Brief Summary
-----------------
Study Objective: To determine whether Natto supplementation in women immediately after menopause might prevent severe bone loss Study population: Women 50 - 60 years, 1-5 years after menopause Study Design: Double-blind, placebo-controlled, randomized controlled trial. A phase II clinical trial. Instruments Used to Measure Therapeutic Response: Lunar Prodigy DEXA bone densitometer Study Treatment Group: Daily supplementation with Vitamin K2, NATTO Study Control Group: Identically-looking placebo medication Duration of treatment: 12 months Duration of Subject Participation in Study: 12 months Assessment of Therapeutic response: Given an expected reduction of bone mass density of - 1.1% annually in the placebo group, the minimum clinically significant difference between the groups is 0.3 percentage points. The trial is therefore powered to detect a reduction in annual bone mass loss of 0.3 percentage points in the treatment group. Numbers of Evaluable Subjects Required: 304 Maximum # Subjects 334

Official Title
-----------------
Phase II Study of Natto Supplementation to Prevent Loss of Bone Mass in Women Immediately After Menopause: a Randomised Double Blind Placebo-Controlled Trial

Conditions
-----------------
Perimenopausal Bone Loss

Intervention / Treatment
-----------------
* Drug: Natto capsules (food suppl.) cont. 360 microg. vit K2/day
* Drug: Placebo capsules


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women living in the city of Tromsø, not using hormone replacement therapy, 1-5 years after menopause. Exclusion Criteria: History of hip fracture Bone disease affecting bone mineral density Use of vitamin K antagonists Significant co-morbidity that makes it difficult to obtain BMD measurements Use of hormone replacement therapy or other therapy that influence bone remodeling

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Natto capsules (food suppl.) cont. 360 microg. vit K2/day|nan|
|Drug: Placebo capsules|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bone mass density |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Women, Bone density, Menopause, Dietary Supplements, Vitamin K2